Chicago Capital LLC lessened its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 82.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,390 shares of the company's stock after selling 130,000 shares during the quarter. Chicago Capital LLC's holdings in MiMedx Group were worth $263,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Jane Street Group LLC lifted its holdings in MiMedx Group by 133.6% in the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock valued at $1,806,000 after purchasing an additional 174,797 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of MiMedx Group by 265.4% in the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock valued at $1,757,000 after buying an additional 215,995 shares during the last quarter. Barclays PLC lifted its stake in shares of MiMedx Group by 163.9% in the third quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after buying an additional 163,005 shares in the last quarter. Farther Finance Advisors LLC boosted its position in MiMedx Group by 88.6% during the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company's stock worth $145,000 after acquiring an additional 11,557 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in MiMedx Group by 299.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock valued at $6,074,000 after acquiring an additional 770,744 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.
MiMedx Group Trading Down 2.2 %
Shares of MDXG traded down $0.19 during mid-day trading on Friday, reaching $8.31. The stock had a trading volume of 426,322 shares, compared to its average volume of 595,969. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of 15.11 and a beta of 1.94. The business's fifty day moving average is $9.10 and its 200 day moving average is $7.57. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.
Wall Street Analyst Weigh In
Separately, StockNews.com lowered shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $12.00.
View Our Latest Stock Analysis on MDXG
MiMedx Group Profile
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
